Antibody Drug Conjugates Market Growth: From USD 5B in 2022 to USD 16.6B by 2030 | CAGR 16.6% Forecast

The Global Antibody Drug Conjugates Market size reached USD 5,032.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 16,594.6 million by 2030. The market is exhibiting at a CAGR of 16.6% during the forecast period (2024-2031)

Antibody Drug Conjugates Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/antibody-drug-conjugates-market?kb

Antibody-Drug Conjugates (ADCs) are a class of targeted cancer therapies that combine an antibody, which specifically targets cancer cells, with a potent drug or chemotherapy agent. The antibody serves as a delivery vehicle, guiding the drug directly to the cancer cells. This allows the drug to be released specifically at the site of the tumor, enhancing the drug's effectiveness while minimizing damage to healthy cells and reducing systemic side effects. ADCs are designed to improve the precision of cancer treatment by selectively targeting tumor cells while sparing normal tissue.

List of the Key Players in the Antibody Drug Conjugates Market:

Takeda Pharmaceutical Company Ltd., Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca, Gilead Sciences Inc., Seagen Inc., Astellas Pharma, Daiichi Sankyo Company Ltd., GlaxoSmithKline Plc, and ADC Therapeutics.

Industry Development:

In May 2023, Sony Corporation, in partnership with Astellas Pharma Inc., announced a collaborative research agreement aimed at developing a novel Antibody-Drug Conjugate (ADC) platform for oncology. This platform will leverage Sony's unique polymeric material, KIRAVIA ADC, designed to precisely deliver anti-cancer drugs to targeted cells, thereby enhancing treatment effectiveness while minimizing side effects associated with damage to healthy cells.

In May 2023, Sutro Biopharma, Inc., an oncology company specializing in site-specific and novel-format ADCs, released its financial results for Q1 2023, along with key business updates and anticipated milestones.

In January 2023, Bridge Biotherapeutics, in collaboration with Pinotbio, signed a memorandum of understanding (MoU) to develop new cancer therapies using their ADC platform technology. Bridge Biotherapeutics will contribute private anticancer targets, while Pinotbio will provide linkers and drugs for the development process.

Growth Forecast Projected:

The Global Antibody Drug Conjugates Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Antibody Drug Conjugates Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/antibody-drug-conjugates-market

Segment Covered in the Antibody Drug Conjugates Market:

By Application: Breast cancer, Blood cancer, Skin cancer, Lung cancer, cancer, Others

By Technology: Non-cleavable linker, Cleavable linker, Linker less

Regional Analysis for Antibody Drug Conjugates Market:

The regional analysis of the Antibody Drug Conjugates Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/antibody-drug-conjugates-market

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Antibody Drug Conjugates market?

➠ Who are the leading manufacturers in the global Antibody Drug Conjugates industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Antibody Drug Conjugates industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Antibody Drug Conjugates market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Browse More Reports: https://www.datamintelligence.com/research-report/antibody-drug-conjugates-market

Cancer Diagnostic Market - https://datamintelligence.com/research-report/cancer-diagnostic-market?kb

Nicotine Patch Market - https://datamintelligence.com/research-report/nicotine-patch-market?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.